Saybrook Capital NC decreased its stake in Johnson & Johnson (NYSE:JNJ – Get Rating) by 1.2% in the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 79,941 shares of the The company’s stock after selling 955 shares during the quarter. Johnson & Johnson makes up about 4.6% of Saybrook Capital NC’s holdings, making the stock its 7th biggest position. the Securities & Exchange Commission.

→ Cash Holders STILL Aren’t Taking Steps to Prepare (From Investor Place Media)

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the stock. Morton Brown Family Wealth LLC increased its stake in shares of Johnson & Johnson by 78.0% during the 2nd quarter. Morton Brown Family LC now Wealth L owns 178 shares of the company’s stock worth $32,000 after purchasing an additional 78 shares during the last quarter. Goodman Advisory Group LLC acquired a new position in shares of Johnson & Johnson during the 2nd quartersha worth $39,000. of Johnson & Johnson by 69.6% during the 2nd quarter. First Bank & Trust now owns 380 shares of the company’s stock worth $67,000 after purchasing an additional 156 shares during the last quarter. Heritage Wealth Management LLC acquired a new position of John & Johnson in share Johnson during the 2nd quarter worth $84,000. Finally, Timber Creek Capital Management LLC grew its stake in Johnson & Johnson by 225.0% in the 3rd quarter. r Creek Capital Management LLC now owns 650 shares of the company’s stock valued at $106,000 after buying an additional 450 shares during the last quarter. Hedge funds and other institutional investors own 67.94% of the company’s stock.

Insider Activity at Johnson & Johnson

In related news, VP Thibaut Mongon sold 35,246 shares of Johnson & Johnson stock in a transaction dated Friday, November 4th. The shares were sold at an average price of $171.18, for a total transaction of $6,033,410.28. Following the completion, of the transaction vice president now directly owns 40,133 shares of the company’s stock, valued at approximately $6,869,966.94. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In related news, EEVP 16,410 shares of Johnson & Johnson stock in a transaction dated Wednesday, November 9th. The shares were sold at an average price of $173.42, for a total transaction of $2,845,822.20. Following the completion of the transaction, the executive vice president 3 owns 1 now direct 7 of the company’s stock, valued at approximately $12,366,753.62. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available ble at the SEC website. Also, VP Thibaut Mongon sold 35,246 shares of the business’s stock in a transaction dated Friday, November 4th. The stock was sold at an average price of $171.18, for a total transaction of $6,033,410.28. Following the completion transaction, the vice president now directly owns 40,133 shares of the company’s stock, valued at $6,869,966.94. The disclosure for this sale can be found here. Insiders sold 233,611 shares of company stock valued at $40,960,735 in day the insiders own 5% 0% the company’s stock.

Analyst Ratings Changes

A number of research firms recently issued reports on JNJ. Morgan Stanley raised their target price on shares of Johnson & Johnson from $176.00 to $180.00 and gave the company an “equal weight” rating in a research note on Wednesday, January 25th. Sanford C. Bernstein lowered their target price on shares of Johnson & Johnson from $194.00 to $190.00 in a research note on Wednesday, October 19th. Credit Suisse Group began coverage on shares of Johnson & Johnson in a research note on Thursday, November 17th. They issued a ” neutral” rating and a $170.00 target price on the stock. Atlantic Securities raised their target price on shares of Johnson & Johnson from $160.00 to $168.00 and gave the company a “neutral” rating in a research note on Wednesday, January 25th. Finally, Citigroup raised their price target on shares of Johnson & Johnson from $198.00 to $205.00 and gave the stock a “buy” rating in a research report on Monday, December 12th. Seven investment analysts have rated the stock w with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $182.75.

Johnson & Johnson Price Performance

NYSE:JNJ opened at $163.42 on Wednesday. The company has a 50-day moving average of $175.08 and a 200-day moving average of $170.69. The company has a market capitalization of $427.26 billion, a price-to-earnings ratio of 24.25, a PEG ratio of 2.79 and a beta of 0.56. Johnson & Johnson has a 52 week low of $155.72 and a 52 week high of $186.69. The company has a debt-to-equity ratio of 0.37, a quick ratio of 1.18 and a current ratio of 1.43.

Johnson & Johnson (NYSE:JNJ – Get Rating) last released its quarterly earnings data on Tuesday, January 24th. The company reported $2.35 EPS for the quarter, topping analysts’ consensus estimates of $2.22 by $0.13. The company had revenue of $23.71 bill the quarter, compared to the consensus estimate of $23.90 billion. Johnson & Johnson had a net margin of 18.90% and a return on equity of 35.94%. The firm’s revenue for the quarter was down 4.4% compared to the same quarter last year. the same period last year, the firm earned $2.13 EPS. As a group, equities research analysts anticipate that Johnson & Johnson will post 10.51 earnings per share for the current fiscal year.

Johnson & Johnson Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 7th. Stockholders of record on Tuesday, February 21st will be issued a dividend of $1.13 per share. This represents a $4.52 dividend on an annualized basis and y ld dividend of 2.77%. The ex-dividend date of this dividend is Friday, February 17th. Johnson & Johnson’s payout ratio is 67.06%.

Johnson & Johnson Profile

(Get Rating)

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment includes products used in the baby care, oral care, beauty, over-the-counter pharmaceutical, women’s health, and wound care markets.

Featured Articles

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or out comments about this story contact@marketbeat.com.

Before you consider Johnson & Johnson, you’ll want to hear this.

MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before market the broader on… and Johnson & Johnson wasn’t on the list.

While Johnson & Johnson currently has a “Hold” rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here